These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 28926193
1. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration. Cobos E, Recalde S, Anter J, Hernandez-Sanchez M, Barreales C, Olavarrieta L, Valverde A, Suarez-Figueroa M, Cruz F, Abraldes M, Pérez-Pérez J, Fernández-Robredo P, Arias L, García-Layana A. Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193 [Abstract] [Full Text] [Related]
7. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N. Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842 [Abstract] [Full Text] [Related]
8. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Hermann MM, van Asten F, Muether PS, Smailhodzic D, Lichtner P, Hoyng CB, Kirchhof B, Grefkes C, den Hollander AI, Fauser S. Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177 [Abstract] [Full Text] [Related]
13. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Maguire MG, Ying GS, Jaffe GJ, Toth CA, Daniel E, Grunwald J, Martin DF, Hagstrom SA, CATT Research Group. JAMA Ophthalmol; 2016 Jun 01; 134(6):674-81. PubMed ID: 27099955 [Abstract] [Full Text] [Related]
14. Investigation of genetic base in the treatment of age-related macular degeneration. Gourgouli K, Gourgouli I, Tsaousis G, Spai S, Niskopoulou M, Efthimiopoulos S, Lamnissou K. Int Ophthalmol; 2020 Apr 01; 40(4):985-997. PubMed ID: 31916060 [Abstract] [Full Text] [Related]
15. Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study. Chang FY, Huang CH, Yang CH, Chang JT, Yang CM, Ho TC, Hsieh YT, Lai TT, Lin CW, Lin CP, Chen YC, Lai YJ, Chen PL, Hsu JS, Chen TC. Clin Exp Ophthalmol; 2024 Aug 01; 52(6):655-664. PubMed ID: 38757252 [Abstract] [Full Text] [Related]
17. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Park UC, Shin JY, Kim SJ, Shin ES, Lee JE, McCarthy LC, Newcombe PJ, Xu CF, Chung H, Yu HG. Retina; 2014 Feb 01; 34(2):288-97. PubMed ID: 23842101 [Abstract] [Full Text] [Related]
18. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. Kuroda Y, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Oishi A, Nakanishi H, Miyake M, Yoshikawa M, Yoshimura N. Am J Ophthalmol; 2016 Jan 01; 161():94-103.e1. PubMed ID: 26432927 [Abstract] [Full Text] [Related]